Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wellin is a consumer health and milk biologics company focused on commercializing MicroLactin, a patented hyper-immune milk protein concentrate marketed as a dietary supplement. The company positions its products around immune support, inflammation reduction, and joint and muscle comfort, particularly for older adults seeking wellness and active-aging solutions. Its lead and apparently core commercial product is Wellin's Microlactin, which contains dairy-derived bioactive components including IgG, IgA, amino acids, and lactoferrin. Based on available public information, Wellin operates more like a wellness and nutraceutical business than a traditional drug-development biotech, with direct-to-consumer sales through its website and marketplace channels. The company appears to have limited disclosed pipeline depth beyond its flagship MicroLactin-based product line.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wellin.